PBS updates

Opdualag (nivolumab + relatlimab)

nivolumab 240 mg/20 mL + relatlimab 80 mg/20 mL injection, 20 mL vial · INJECTION · PBS code 14664T

STREAMLINED

What it costs

AU$9097.9 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2024-12-01.
  • • Repeats: 8.
  • • PBS program: IN.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Unresectable Stage III or Stage IV malignant melanoma


Initial treatment


Patient must not have received prior treatment with ipilimumab or a PD-1 (programmed cell death-1) inhibitor for the treatment of unresectable Stage III or Stage IV malignant melanoma; AND

Patient must not have experienced disease progression whilst on either: (i) PD-1 inhibitor treatment, (ii) CTLA-4 inhibitor treatment, if previously treated for resected or resectable melanoma; or

Patient must not have experienced disease recurrence within 6 months of completing either: (i) PD-1 inhibitor treatment, (ii) CTLA-4 inhibitor treatment, if previously treated for resected or resectable melanoma; AND

Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; AND

The condition must not be uveal melanoma; AND

The treatment must be the sole PBS-subsidised therapy for this condition; AND

Patient must weigh 40 kg or more; AND

Patient must be at least 12 years of age.

Patients must only receive a maximum of 480 mg nivolumab and 160 mg relatlimab every four weeks under a flat dosing regimen.

The prescribed dose must be according to the Therapeutic Goods Administration (TGA) Product Information.

The prescription must include the amount of nivolumab with relatlimab (Opdualag) that is appropriate to be prescribed for the patient. For the purposes of PBS subsidy, the maximum amount requested is based on the nivolumab dose only. The prescribed amount of nivolumab must be expressed in milligrams.

Sponsor: Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.